Clinical trials: Hypertrophic
Nonmalignant Neoplasm, Prostate Cancer
MRI and Magnetic Resonance Spectroscopy Imaging in Patients Receiving Dutasteride for Benign Prostatic Hypertrophy and Low-Risk Prostate Cancer
RATIONALE: Diagnostic procedures, such as MRI and magnetic resonance spectroscopy imaging, may help in learning how well dutasteride works in patients with benign prostatic hypertrophy and low-risk prostate cancer.
- Trial name
- NCT00706966
- Testing
- dutasteride
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of California, San Francisco
Pain, Postoperative, Tonsillar Hypertrophy
Management of Post-Tonsillectomy Pain in Pediatric Patients
Single-center, randomized, open-label, non-inferiority treatment pilot study to evaluate the effectiveness of a combined acetaminophen and ibuprofen regimen for treatment of post-operative tonsillectomy pain in the pediatric…
- Conditions
- Pain, Postoperative, Tonsillar Hypertrophy, Tonsillitis
- Trial name
- NCT04551196
- Testing
- Alternating Acetaminophen and Ibuprofen, Combined Acetaminophen and Ibuprofen
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Washington University School of Medicine
Benign Prostatic Hyperplasia
A Study in Men With Benign Prostatic Hyperplasia
The purpose of the study is to determine whether LY500307 helps symptoms of Benign Prostatic Hyperplasia (BPH)
- Trial name
- NCT01097707
- Testing
- LY500307
- Where
- 70 sites in United States, Australia and 6 more
- Volunteers
- 414 people
- Sponsor
- Eli Lilly and Company
ALPS, Hypersplenism
Valproic Acid (Depakote[Registered Trademark]) to Treat Autoimmune Lymphoproliferative Syndrome (ALPS)
This study will test whether valproic acid (Depakote[Registered Trademark]) can shrink enlarged lymph glands and spleen in patients with autoimmune lymphoproliferative syndrome (ALPS).
- Conditions
- ALPS, Hypersplenism, Lymphadenopathy
- Trial name
- NCT00605657
- Testing
- Valproic Acid, CT Scan, Blood Sample
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Koneti Rao
Fibrosis, Skin Scarring
Light Emitting Diode-Red Light (LED-RL) Phototherapy for Skin Scarring Prevention
Skin scarring (fibrosis) is a common complication in the wound healing process and remains a therapeutic challenge. Scar formation often occurs following injury to the skin such as surgery, trauma, and burns.
- Conditions
- Fibrosis, Skin Scarring, Skin Wound, Hypertrophic Scar
- Trial name
- NCT03795116
- Testing
- LED-RL phototherapy, Mock irradiation
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- State University of New York - Downstate Medical Center
Myocardial Infarction, Heart Failure
Study of Oral PG-116800 Following a Heart Attack
The main purpose of the study is to test whether a possible new drug (called PG-116800) can prevent some of the damage to heart muscle in patients who have had a heart attack.
- Conditions
- Myocardial Infarction, Heart Failure, Heart Enlargement
- Trial name
- NCT00067236
- Testing
- PG-116800 (given as PG-530742)
- Where
- 52 sites in United States, Canada and 1 more
- Volunteers
- 253 people
- Sponsor
- Procter and Gamble
Ann Arbor Stage II Grade 1 Follicular Lymphoma, Ann Arbor Stage II Grade 2 Follicular Lymphoma
Obinutuzumab and Lenalidomide in Treating Patients With Previously Untreated Stage II-IV Grade 1-3a Follicular Lymphoma
This phase II trial studies how well obinutuzumab and lenalidomide work in treating patients with previously untreated stage II-IV grade 1-3a follicular lymphoma.
- Conditions
- Ann Arbor Stage II Grade 1 Follicular Lymphoma, Ann Arbor Stage II Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 1 Follicular Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma
- Trial name
- NCT02871219
- Testing
- Lenalidomide, Obinutuzumab
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- M.D. Anderson Cancer Center
Acne Scars - Mixed Atrophic and Hypertrophic
Tripeptide/Hexapeptide Topical and Hybrid Laser Treatment for Acne Scarring
To evaluate the efficacy of a tripeptide/hexapeptide topical (Alastin Regenerating Skin Nectar with TriHex Technology®) in wound healing and scar reduction following Erbium:YAG hybrid resurfacing laser for acne scarring compared…
- Trial name
- NCT04606134
- Testing
- Hybrid fractional laser, Alastin Regenerating Skin Nectar with TriHex Technology, Cetaphil face cream
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Rochester
Adenotonsillar Hypertrophy, Obstructive Sleep Apnea
The Effect of Dexmedetomidine on Airway Complications After Deep or Awake Extubation
The investigators aim to investigate the effect of dexmedetomidine on the perioperative respiratory complications in this patient population undergoing both awake and deep tracheal extubation.
- Conditions
- Adenotonsillar Hypertrophy, Obstructive Sleep Apnea, Tonsillitis, Adenoiditis
- Trial name
- NCT02162433
- Testing
- Normal Saline, Dexmedetomidine
- Where
- United States
- Volunteers
- 92 people
- Sponsor
- Massachusetts Eye and Ear Infirmary
Reduction of Hypertrophic Skin Scarring
Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery
The study will compare how well PF-06473871 works versus placebo in reducing skin scarring after scar revision surgery of existing breast scars. The study will also evaluate the safety of PF-06473871 in healthy adult subjects.
- Trial name
- NCT01730339
- Testing
- PF-06473871
- Where
- 40 sites in United States, Germany and 2 more
- Volunteers
- 103 people
- Sponsor
- Pfizer
Cardiomyopathy, Hypertrophic
A Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy
The purpose of this study is to evaluate the safety, tolerability, and efficacy of mavacamten compared with placebo in participants with symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM).
- Trial name
- ODYSSEY-HCM (NCT05582395)
- Testing
- Mavacamten
- Where
- 224 sites in United States, Australia and 21 more
- Volunteers
- 580 people
- Sponsor
- Bristol-Myers Squibb
Diffuse Large-cell B-cell Lymphoma
Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL)
The purpose of this study is to investigate the safety and effectiveness of plamotamab when it is given with tafasitamab and lenalidomide in participants with relapsed or refractory DLBCL.
- Trial name
- NCT05328102
- Testing
- Plamotamab, Tafasitamab, Lenalidomide
- Where
- 3 sites in United States, France and 1 more
- Volunteers
- 3 people
- Sponsor
- Xencor, Inc.
Adenoids Hypertrophy
Efficacy and Safety of Mometasone Furoate Nasal Spray in Children With Adenoid Hypertrophy. SNORE Study (P05155)
The purpose of this study is to determine whether 8 weeks treatment with mometasone furoate nasal spray (MFNS), twice daily, is safe and effective in treating adenoid hypertrophy in children.
- Trial name
- SNORE (NCT00552032)
- Testing
- Mometasone Furoate nasal spray
- Volunteers
- 132 people
- Sponsor
- Organon and Co
Hypertrophic Scars Resulting From Prior Breast Scar Revision Surgery
A Phase 2 Extension Study To Enroll Subjects Who Were Enrolled In B5301001 Study
Study is a multicenter, two-part, open-label phase II study in adults, evaluating the safety and long-term efficacy of PF-06473871 one year after surgical revision and treatment with PF-06473871.
- Trial name
- NCT02205476
- Testing
- PF-06473871
- Where
- 5 sites in United States
- Volunteers
- 10 people
- Sponsor
- Pfizer
Prostatic Hyperplasia
Benign Prostatic Hypertrophy Treatment Patterns & Outcomes: Marketscan
This retrospective study aims to assess treatment patterns within 1 year of initiating BPH treatment, including 5-alpha-reductase inhibitor (5ARI) monotherapy, alpha-blocker (AB) monotherapy, early combination therapy, and…
- Trial name
- NCT01323998
- Testing
- 5ARI, AB
- Volunteers
- 35,032 people
- Sponsor
- GlaxoSmithKline
HIV Posterior Cheek Enlargement
HIV Posterior Cheek Enlargement
Altered contour of the lower face is a frequent complication of human immunodeficiency virus (HIV). HIV facial lipoatrophy or loss of facial fat commonly results from antiretroviral therapy.
- Trial name
- NCT01635504
- Testing
- Botulinum toxin A
- Where
- Canada
- Volunteers
- 5 people
- Sponsor
- University of British Columbia